Figure 1.
Event-free survival, overall survival, and cumulative incidence to relapse of patients treated on AAML0431 and A2971 ARM B. (A) EFS for n = 204 eligible patients on AAML0431 and n = 126 eligible patients 0 to 4 year olds with AML/MDS on A2971. (B) OS for n = 204 eligible patients on AAML0431 and n = 126 eligible patients 0 to 4 year olds on A2971, arm B. (C) Cumulative incidence of relapse for patients classified with AML (n = 144) and MDS (n = 60).